Adamax is one of the fastest-rising names in the research-peptide market, and the questions people ask about it are the ones every new name attracts: how much, how often, for how long. The honest answer is short. There is no study of Adamax in people, so there is no dose. What exists is a set of figures that vendors and dosing sites publish, which those same sites describe as conventions rather than findings. This page reports those figures exactly, says where each came from, checks the arithmetic, and records one thing a reader would not expect: a product sold as Adamax whose own specification names a different molecule. What Adamax is claimed to be, and the registry search that found nothing, are on our Adamax vs Semax page.
Why there is no human dose
A dose figure that means something comes from one of a small number of places: an approved label, a trial protocol, a formulary, or a published study that measured an effect at a stated amount. Adamax has none of them. When this site checked on 9 October 2026, ClinicalTrials.gov, PubChem, the openFDA adverse-event database and PubMed had no record of the compound — PubMed's 39 hits for the word were all a machine-learning optimiser of the same name. No regulator has reviewed it. The structure itself has not been published anywhere a chemist could check.
The figures in circulation, and what their publishers say about them
| Source (date read) | Figure | Route and schedule | What the source says the figure rests on |
|---|---|---|---|
| Dosing guide on a peptide catalogue site (published 2026-07-27; read 2026-10-11) | ~100–300 mcg per administration | Intranasal or subcutaneous; once daily or every other day; ~2–4 weeks on, then a break | "Community/vendor convention"; figures "appear to be scaled down from typical Semax nasal doses"; "no validated human dose for Adamax" |
| Protocol site (last reviewed August 2026; read 2026-10-11) | 300 → 500 → 750 → 1,000 mcg a day, two weeks each | Subcutaneous, once daily, 8 weeks | "Community-derived and not trial-validated"; "no clinical trial has established an Adamax dose, route, or cycle" |
| Same protocol site, nasal section | "Often a few hundred micrograms" per dose | Intranasal; some split into morning and midday | Community reports; "no tested dose" |
| Vendor product page "Adamax nasal spray" (read 2026-10-11) | 100 mcg per spray, 100 sprays per 10 mg bottle | Intranasal | Product specification — see below for what the specification names |
Two things stand out. Every publisher, including the ones that sell or earn commissions on the product, states in its own words that the figures are not from any study. And the figures are not consistent with each other: the protocol site's injected schedule ends at more than three times the catalogue site's upper figure, and the protocol site's comparison table calls its injected amounts "a few hundred micrograms per day" while its schedule climbs to 1,000.
Checking the arithmetic
The protocol site's planning numbers are internally consistent. Our check:
| Weeks | Daily figure | Days | Subtotal |
|---|---|---|---|
| 1–2 | 300 mcg | 14 | 4.2 mg |
| 3–4 | 500 mcg | 14 | 7.0 mg |
| 5–6 | 750 mcg | 14 | 10.5 mg |
| 7–8 | 1,000 mcg | 14 | 14.0 mg |
| Total | 56 | 35.7 mg |
That matches the site's 35.7 mg and its "four 10 mg vials". Its volumes also check: a 10 mg vial in 3 mL is 3.33 mg/mL, so 300 mcg is 0.09 mL and 1,000 mcg is 0.30 mL. Arithmetic being right says nothing about whether the amounts are; it only means the site did the division correctly.
The more useful calculation is about molecules, because the potency claim is a molecule-for-molecule claim. Using the weights in our Adamax vs Semax table:
| Molecule | Weight | Molecules in 1 mg | Mass with the same molecules as 300 mcg of Adamax |
|---|---|---|---|
| Adamax (as vendors state it) | 1,032.2 | 0.969 µmol | 300 mcg |
| N-acetyl Semax amidate | 855.0 | 1.170 µmol | ≈ 248 mcg |
| Semax | 813.9 | 1.229 µmol | ≈ 237 mcg |
So 300 mcg of Adamax carries about a fifth fewer molecules than 300 mcg of Semax. The claim that Adamax is "2–3 times as potent" — which the dosing guide reports and calls unverified — would have to be measured, not assumed; nobody has published a measurement. The Semax figures it is being scaled from are themselves thin: the published Semax doses are percentages of a nasal solution with no stated instilled volume, as our Semax dosage page explains.
One "Adamax" product names a different molecule
A vendor page headed "buy adamax nasal spray", read on 11 October 2026, gives the composition as "N-Acetyl Semax Amidate (Ac-MEHFPGPAG-NH2), single compound, 10mg/100 sprays (100mcg/spray)". N-acetyl Semax amidate is a known Semax derivative with a PubChem record (855.0 Da). It is not the 1,032 Da adamantane-bearing molecule other vendors describe as Adamax.
We do not know whether the page is mislabelled, whether that vendor uses "Adamax" as a brand name for N-acetyl Semax amidate, or whether the contents match either description; no independent analysis has been published. What it establishes is narrower and still important: the name Adamax on a label does not identify a single molecule, so a dose figure written for one product cannot be assumed to describe another. A certificate of analysis can confirm a mass; it cannot confirm a structure that no reference defines — see how to read a COA.
Side effects, briefly
There is no published adverse-event record. The protocol site lists nasal irritation or dryness, injection-site redness or swelling, and anecdotal headache, restlessness, irritability and sleep changes, and states that Adamax "does not have a published side-effect dataset". Semax's own small record is set out on our Semax side-effects page; it does not transfer to a different molecule.
What is not established
- Any human dose, by any route.
- Any pharmacokinetic measurement — absorption through the nose, half-life, brain penetration (the claimed reason for the adamantane group).
- Any comparison with Semax that would support a potency ratio.
- Any safety observation from a study, of any length.
- A defined structure in a public register, against which a vial's contents could be checked.
These figures are reported so readers can see where they come from and what they rest on, not as a guide to use. Anyone considering a compound with no human data should take the question to a clinician. The wider cognitive category is covered in our guide to cognitive peptides, and how to read any dose figure's provenance is on our page on how to read a dosing claim.
Sources and dates
- Peptide catalogue site, Adamax dosing guide, published 2026-07-27. https://thepeptidecatalog.com/articles/adamax-dosing-guide. Read 2026-10-11.
- Peptide dosing protocol site, Adamax, last reviewed August 2026. https://www.peptidedosingprotocols.com/protocol/adamax. Read 2026-10-11.
- Vendor product page, "buy adamax nasal spray", composition and specification table. https://pspeptides.com/product/buy-adamax-nasal-spray/. Read 2026-10-11.
- PubChem: Semax CID 9811102 (813.9); N-acetyl Semax amidate CID 172638603 (855.0); Adamax formula as vendors state it (C50H69N11O11S), weight calculated by us (1,032.2), as recorded on our Adamax vs Semax page (read 2026-10-09).
- Registry and database searches (ClinicalTrials.gov, PubChem, openFDA, PubMed) for "Adamax", run for our Adamax vs Semax page on 2026-10-09.